市場調查報告書

症候群多重診斷的全球市場:成長率,趨勢及預測

Syndromic Multiplex Diagnostic Market - Growth, Trends, and Forecast (2020 - 2025)

出版商 Mordor Intelligence LLP 商品編碼 921984
出版日期 內容資訊 英文 115 Pages
商品交期: 2-3個工作天內
價格
症候群多重診斷的全球市場:成長率,趨勢及預測 Syndromic Multiplex Diagnostic Market - Growth, Trends, and Forecast (2020 - 2025)
出版日期: 2020年01月01日內容資訊: 英文 115 Pages
簡介

本報告提供全球症候群多重診斷市場相關調查分析,提供市場概要,市場動態,市場區隔,各地區的市場分析,競爭情形,主要企業等相關的系統性資訊。

目錄

第1章 簡介

  • 調查的成果
  • 調查的前提條件
  • 調查範圍

第2章 調查方法

第3章 摘要整理

第4章 市場動態

  • 市場概況
  • 市場成長要素
    • 對準確,快速結果的需求增加
    • 快速治療和減少抗生素副作用的機會
  • 市場阻礙因素
    • 醫生不願和缺乏熟練的專業人員
    • 不可發現的無症狀病例
  • 波特的五力分析
    • 新加入廠商的威脅
    • 買主/消費者談判力
    • 供應商談判力
    • 替代產品的威脅
    • 競爭力的強度

第5章 市場區隔

  • 各症候群類型
    • 呼吸系統
    • 腸胃
    • 中樞神經系統
    • 其他
  • 各終端用戶
    • 醫院
    • 診斷研究所
    • 其他
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東·非洲地區
    • 南美

第6章 競爭情形

  • 公司概要
    • BIOMERIEUX SA
    • Qiagen
    • Luminex Corporation
    • Applied BioCode
    • Akonni Biosystems
    • Mesa Biotech
    • Abbott
    • Accelerate Diagnostic
    • Diagenode Diagnostics
    • Hologic

第7章 市場機會及未來趨勢

目錄
Product Code: 67634

Market Overview

The syndromic multiplex diagnostic market studied was anticipated to grow with a CAGR of nearly 7.2% during the forecast period. The major factors attributing to the growth of the syndromic multiplex diagnostic market are a rise in the number of infectious cases and diseases and higher incidences of side effects associated with the use of antibiotics which demand the necessity of diagnostics. Thus, owing to its ability to address the rising needs of the patients and clinicians like utilization of lesser resources, enhanced accuracy of results led the syndromic multiplex diagnostic market to grow throughout the forecast period. For instance, in May 2018, according to the World Health Organization, the leading cause of deaths recorded worldwide was lower respiratory infections necessitating the high requirement for advanced diagnostic equipment which fuel the global syndromic multiplex diagnostic market.

Scope of the Report

The syndrome is a collection of abnormal signs and symptoms that are often associated with a specific disease where identification of the specific causative agent is difficult in order to take precautions in advance or give appropriate treatment for the patients. The syndromic multiplex diagnostic test employs testing of various pathogens in a single test reaction, helps healthcare providers to deliver efficient medications in proper time by minimizing uncertainty and mistakes that occur while testing of an infection. The syndromic multiplex diagnostic test gives more accurate, realistic and comprehensive results in critical care.

Key Market Trends

Respiratory by Type of Syndrome is Expected to Hold the Major Market Share in the Syndromic Multiplex Diagnostic Market

  • Respiratory syndromes account for the largest share of the syndromic multiplex diagnostics market and expected to continue the same throughout the forecast period. This dominance mainly due to factors such as the higher demand due to the rapid spread of infections along with the launch of new products with USFDA approvals in the segment that contributes to its major revenue share in the global market.
  • By End-user, hospitals account for the largest share due to the availability of all resources at a single facility. Also, the reduction of the overall stay of patients for treatment in hospitals with the reduced procedural time along with minimal or no uncertainties, and errors in the treatments is expected to fuel the market during the forecast period.

North America Dominates the Market and Expected to do Same in the Forecast Period.

North America has been the primary market for the syndromic multiplex diagnostic market and is expected to hold a significant share in global revenue owing to the adoption of advanced technologies and the availability of improved healthcare infrastructure, and also rise in R&D laboratories resultant.

Europe has been the second-largest market for syndromic multiplex diagnostic market, where the market is fueled by the increased healthcare expenditure, and preference of patients for novel treatment procedures.

Globally, the syndromic multiplex diagnostics market is expected to witness the fastest growth in the Asia-Pacific region during the forecast period due to the higher demand for treatments with widespread infections, rise in government support to spread the healthcare awareness among people about various infections in the region.

Competitive Landscape

The Global Syndromic multiplex diagnostic market is moderately competitive and consists of several major players. In terms of market share, few of the major players are currently dominating the market. Some prominent players are launching new products, while others are distributing the products, making acquisitions and partnerships to increase their footprints in the market. For instance, in June 2019, Biomerieux received approval for their Novel TruDiagnosis System by Food and Drug Administration (FDA) which is specially designed for the diagnosis of multiple infections. The unique microfluidic design in a single chamber result in a much faster workflow and a cost-effective consumable for multiplexed testing as compared to traditional technologies. Some of the companies which are currently dominating the market are BIOMERIEUX SA, Luminex Corporation, QIAGEN, Applied BioCode, and Akonni Biosystems.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Demand for Accurate and Rapid Results
    • 4.2.2 Quick Access to the Treatment and Reduction of the Adverse Reactions of Antibiotics
  • 4.3 Market Restraints
    • 4.3.1 Reluctance by Doctors and lack of Skilled Professional
    • 4.3.2 The Inability in Detecting Asymptomatic Cases
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Type of Syndrome
    • 5.1.1 Respiratory
    • 5.1.2 Gastrointestinal
    • 5.1.3 Central Nervous System
    • 5.1.4 Others
  • 5.2 By End-user
    • 5.2.1 Hospitals
    • 5.2.2 Diagnostics Laboratories
    • 5.2.3 Others
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 BIOMERIEUX SA
    • 6.1.2 Qiagen
    • 6.1.3 Luminex Corporation
    • 6.1.4 Applied BioCode
    • 6.1.5 Akonni Biosystems
    • 6.1.6 Mesa Biotech
    • 6.1.7 Abbott
    • 6.1.8 Accelerate Diagnostic
    • 6.1.9 Diagenode Diagnostics
    • 6.1.10 Hologic

7 MARKET OPPORTUNITIES AND FUTURE TRENDS